SITE008-0136

SITE008 (KOR) › SITE008-0136

SITE008-0136

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE008 (KOR) · Dr. Kim
consented 2026-02-09

enrolled

AEs

4

Serious

0

Dropout signal

–

Adverse events

4

Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-02-20 (study day 189); relationship: NOT RELATED

mild assessed

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-02-18 (study day 187); relationship: not assessed

moderate assessed

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-01-13 (study day 151); relationship: not assessed

moderate assessed

Grade 3 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-01-01 (study day 139); relationship: not assessed

severe assessed

Data queries

0

No data queries. Open queries would appear here for this patient.